Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Helps, Yet It Is Underused in Some with NLPHL

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 22; Bismarck, et al

Radiotherapy (RT) is linked with longer overall survival in patients with any stage of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL), according to a study involving nearly 2,000 individuals. Still, it is less likely to be used in those who are in an advanced-stage and have B-symptoms. Participants were a median 46 years of age and were diagnosed with NLPHL between 2004 and 2012. Investigators looked at overall survival and survival differences between treatment groups. Among the results:

  • Increasing age, black race, Medicare insurance, chemotherapy use, stage II-IV disease, and presence of B-symptoms predicted RT omission.
  • Overall, patients receiving RT survived ~50 months, vs ~42 months for those who didn’t receive such, even after multivariate analysis.
  • Patients with B symptoms who received RT survived an average of 49 months, vs ~43 months for those who didn’t receive such.


Bismarck O, Boothe D, Frandsen J, Poppe M, Gaffney D. The role of radiation in all stages of nodular lymphocytic predominant Hodgkin lymphoma. [Published online ahead of print September 22, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.013.

This Week's Must Reads

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P

Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.

New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.